Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315702919> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4315702919 endingPage "e43" @default.
- W4315702919 startingPage "e42" @default.
- W4315702919 abstract "Objective: To evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the highly potent, selective small-molecule inhibitor of aldosterone synthase (CIN-107) in a randomized, double-blind, placebo-controlled phase 1 study in healthy volunteers. Design and methods: Subjects were randomized into 5 cohorts to receive CIN-107 or placebo once daily for 10 days. Cohorts 1 and 2 were placed on a low salt diet to stimulate aldosterone production and were administered 2.5 or 5.0 mg oral CIN-107, respectively. They also underwent an adrenocorticotropic hormone challenge to increase aldosterone and cortisol levels to evaluate the specificity of CIN-107 for aldosterone synthase. Cohorts 3, 4, and 5 were placed on a normal salt diet and were administered 1.5, 2.5, or 0.5 mg oral CIN-107, respectively. Blood samples were collected prior to and after dosing on days 1 and 10 for measurement of plasma CIN-107 concentrations to characterize single-dose and steady-state pharmacokinetics. Pharmacodynamic measurements included aldosterone, cortisol, and electrolytes. Safety assessments included physical examination, electrocardiograms, orthostatic vital signs, and clinical laboratory evaluations, including renal function. Results: Fifty-four subjects completed the study. There were no deaths, serious adverse events, or discontinuations due to treatment-emergent adverse events (TEAEs). All TEAEs in subjects receiving CIN-107 were mild in severity. Plasma concentrations of CIN-107 increased proportionally with ascending doses. CIN-107 was rapidly absorbed, with peak concentrations observed within 4 hours after dosing. Mean half-life was 26–31 hours. A dose-dependent reduction of plasma aldosterone occurred with CIN-107 doses ≧1.5 mg, regardless of normal or low salt diet. Decreases in plasma aldosterone started on Day 1 and were sustained, with levels reduced by approximately 51–73% on Day 10 (Figure 1). CIN-107 had no meaningful impact on plasma cortisol levels. The urine sodium:potassium ratio increased on Day 1 and diminished by Day 10, an effect mediated by greater elimination of sodium on Day 1 compared to Day 10. A mild increase in the blood urea nitrogen:creatinine ratio and a mild reduction in the glomerular filtration rate (<15%) suggest that CIN-107 produced a mild diuretic effect. Conclusions: CIN-107 was safe and well tolerated and resulted in dose-dependent increases in plasma CIN-107 with a half-life that supports once-daily dosing. The dose-dependent decrease in plasma aldosterone, transient increase in sodium excretion, and mild diuretic effect support continued study in ongoing phase 2 clinical trials evaluating the efficacy and safety of CIN-107 for treatment-resistant or uncontrolled hypertension and primary aldosteronism." @default.
- W4315702919 created "2023-01-12" @default.
- W4315702919 creator A5020426982 @default.
- W4315702919 creator A5039558708 @default.
- W4315702919 creator A5047975710 @default.
- W4315702919 creator A5054426924 @default.
- W4315702919 creator A5062733502 @default.
- W4315702919 date "2023-01-01" @default.
- W4315702919 modified "2023-09-27" @default.
- W4315702919 title "S-16-4: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY RESULTS FROM A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR CIN-107" @default.
- W4315702919 doi "https://doi.org/10.1097/01.hjh.0000913124.11105.5b" @default.
- W4315702919 hasPublicationYear "2023" @default.
- W4315702919 type Work @default.
- W4315702919 citedByCount "0" @default.
- W4315702919 crossrefType "journal-article" @default.
- W4315702919 hasAuthorship W4315702919A5020426982 @default.
- W4315702919 hasAuthorship W4315702919A5039558708 @default.
- W4315702919 hasAuthorship W4315702919A5047975710 @default.
- W4315702919 hasAuthorship W4315702919A5054426924 @default.
- W4315702919 hasAuthorship W4315702919A5062733502 @default.
- W4315702919 hasBestOaLocation W43157029191 @default.
- W4315702919 hasConcept C111113717 @default.
- W4315702919 hasConcept C112705442 @default.
- W4315702919 hasConcept C126322002 @default.
- W4315702919 hasConcept C134018914 @default.
- W4315702919 hasConcept C142724271 @default.
- W4315702919 hasConcept C197934379 @default.
- W4315702919 hasConcept C204787440 @default.
- W4315702919 hasConcept C27081682 @default.
- W4315702919 hasConcept C2777288759 @default.
- W4315702919 hasConcept C2778525890 @default.
- W4315702919 hasConcept C71924100 @default.
- W4315702919 hasConcept C90924648 @default.
- W4315702919 hasConcept C98274493 @default.
- W4315702919 hasConceptScore W4315702919C111113717 @default.
- W4315702919 hasConceptScore W4315702919C112705442 @default.
- W4315702919 hasConceptScore W4315702919C126322002 @default.
- W4315702919 hasConceptScore W4315702919C134018914 @default.
- W4315702919 hasConceptScore W4315702919C142724271 @default.
- W4315702919 hasConceptScore W4315702919C197934379 @default.
- W4315702919 hasConceptScore W4315702919C204787440 @default.
- W4315702919 hasConceptScore W4315702919C27081682 @default.
- W4315702919 hasConceptScore W4315702919C2777288759 @default.
- W4315702919 hasConceptScore W4315702919C2778525890 @default.
- W4315702919 hasConceptScore W4315702919C71924100 @default.
- W4315702919 hasConceptScore W4315702919C90924648 @default.
- W4315702919 hasConceptScore W4315702919C98274493 @default.
- W4315702919 hasIssue "Suppl 1" @default.
- W4315702919 hasLocation W43157029191 @default.
- W4315702919 hasLocation W43157029192 @default.
- W4315702919 hasOpenAccess W4315702919 @default.
- W4315702919 hasPrimaryLocation W43157029191 @default.
- W4315702919 hasRelatedWork W1967659878 @default.
- W4315702919 hasRelatedWork W2005378862 @default.
- W4315702919 hasRelatedWork W2017346924 @default.
- W4315702919 hasRelatedWork W2024736606 @default.
- W4315702919 hasRelatedWork W2067328017 @default.
- W4315702919 hasRelatedWork W2089173316 @default.
- W4315702919 hasRelatedWork W2096740894 @default.
- W4315702919 hasRelatedWork W3021369409 @default.
- W4315702919 hasRelatedWork W4234160658 @default.
- W4315702919 hasRelatedWork W2101116529 @default.
- W4315702919 hasVolume "41" @default.
- W4315702919 isParatext "false" @default.
- W4315702919 isRetracted "false" @default.
- W4315702919 workType "article" @default.